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In order to analyze the role of Fzd7 in endothelial cell function, effect of Fzd7 knock down by small interfering RNAs was investigated in human umbilical vein endothelial cells (HUVEC). KD of Fzd7 had no effect on cell proliferation whereas a strong inhibition of HUVEC migration and tube formation was observed. Indeed, Fzd7 siRNA decreased cell migration to 59±17 % (n=3, p<0.0001) compared to control siRNA in transwell assay. We also found that HUVEC transfected with control siRNA form well-connected tubular structures in Matrigel assay after 18h, whereas Fzd7 siRNA treated HUVEC showed a strong delay in tubular structures formation (43±5 tubes/À eld in control vs 15±7 in Fzd7 siRNA, p<0.0001).
This À nding suggests that Fzd7 may play a crucial role during vascular formation. Fzd7 is essential for zebraÀ sh vascular development in vivo and regulates endothelial cells functions involved in angiogenesis in vitro. MicroCT and immunohistochemistry approaches revealed that Fzd4 deletion altered dramatically coronary and arterial network formations in the heart and in the kidney with a signiÀ cant decrease of the arterial branching. Micro-array analysis revealed that in hearts of Fzd4 KO neonate mice, the primary effect of Fzd 4 deletion was the down-regulation of the cell cycle-regulating transcription factor E2F1, with a decreased expression of a large number of E2F target genes. This observation indicated that loss of Fzd4 lead to cell cycle arrest.
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FRIZZLED 4 REGULATES VASCULAR FORMATION IN MICE
We conducted in vitro studies to conÀ rm the role of Fzd4 on cell cyle response on murine embryonic À broblasts (MEF) and endothelial cells (EC) isolated from KO Fzd4 vs Wt mice. Fzd4 KO reduced MEF and EC proliferation. Fzd4 siRNA-mediated knockdown (KD) in EC delayed G1 to S cell cycle entry compared to that in control EC (transition G1 to S at 12H, 3,5 % vs 14,5 % vs control EC). In vitro matrigel assay showed that Fzd4 KD reduced the differentiation of HUVEC to form capillary structures under VEGF A-stimulation (43±4 in Fzd4 KD EC vs 28± 7, in control EC, P<0.005) but did not modify EC migration compared to control EC in a transwell migration assay.
These À ndings are the À rst to show that a frizzled member Fzd4 can repress E2F1 cell cycle progression in EC independently of the Wnt/β catenin canonical pathway and affects deeply vascular formation and branching.
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MESENCHYMAL STEM CELLS PROTECT CARDIOMYOCYTES FROM REPERFUSION INJURY THROUGH A PARACRINE ACTIVATION OF THE PI3 KINASE PATHWAY
D. ANGOULVANT 1 , F. IVANES 1 , R. FERRERA 1 , P.G. MATTHEWS 1 , S. NATAF 2 , N. CHERIAA 1 , M. OVIZE 1 1 Inserm U886,
Université Claude Bernard Lyon 1, Lyon, France 2 Inserm U842, Université Claude Bernard Lyon 1, Lyon, France
Objectives -Previous data suggest that implantation of mesenchymal stem cells (MSCs) improves heart function after myocardial infarction. We investigated whether protection afforded by MSCs might involve a paracrine activation of the PI3 kinase pathway in reperfused cardiomyocytes.
Method -MSCs and neonatal rat cardiomyocytes (NRCs) were isolated and cultured separately. NRCs (2.106) were subjected to 5 hours of ischemia followed by 16 hours of reperfusion. At the time of reperfusion, NRCs (n=8-14/group) received either fresh medium (control group), or the following treatments: MSCs ( Conclusion -our data suggest that MSCs can protect NRCs from reperfusion injury through a paracrine activation of the PI3K pathway. Background -Myocardial infarction (MI) in mice with mutations in the stem cell factor (SCF) receptor causes rapid heart failure. Implantation of mesenchymal stem cells (MSC) slows progression to heart failure after MI. We hypothesized that MSC engineered to over-express SCF would restore cardiac function better than unmodiÀ ed MSC.
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MESENCHYMAL STEM CELLS ENGINEERED TO OVEREXPRESS STEM CELL FACTOR IMPROVE CARDIAC FUNCTION BUT HAVE MALIGNANT POTENTIAL
Methods -MSC from C57Bl/6 mice bone marrow were transfected with SCF cDNA cloned into pcDNA-3, and a stable transfectant was selected in G418 medium. C57Bl/6 mice (N) underwent coronary ligation and received medium (M), or 3x105 MSC (C) or MSC transfected with SCF (CS) into the anterior left ventricle. Cardiac function was assessed by pressure-volume (PV) loops on day 28 (n=10 per group). Hearts were perfusion-À xed in situ and cut into transverse sections for computerized planimetry (n=5 per group).
Results -When measured in vivo, myocardial SCF increased 2.9fold in M, 5.5-fold in C, and 17.3-fold in SC groups compared to the N group (P<0.05). All analysis showed signiÀ cant improvement of post MI ventricular size and function in cell groups compared to M group. PV loop analysis showed a 1.9-fold increase (P < 0.001) in the slope of preload-recruitable stroke work in CS group compared with C group. The improvement in end-systolic elastance was similar to the improvement in preload-recruitable stroke work. In addition, the left ventricular volume was 0.6-fold smaller (P<.01) in the CS group compared with the C group. However 4 out of 20 survivors in CS group developed À brosarcomas inÀ ltrating into the cell transplanted area within 3 months of cell implantation.
Conclusions -Use of genetically modiÀ ed MSC over-expressing SCF better prevented ventricular dilation and restored cardiac function following MI. Unfortunately, this approach was associated with tumorogenesis and our data strongly suggests that malignant transformation was caused by the speciÀ c combination of techniques that we used to generate our cell line. Therapeutic angiogenesis is a promising approach to re-establish cardiac perfusion following ischemia or in heart failure. Recently, it has been proposed that a combination of growth factors may be key to the generation of stable vascular networks. However, it is currently unknown what growth factor combinations are optimal for therapeutic angiogenesis and what mode of administration is most adapted to achieve functional revascularization of the heart.
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DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES TO STIMULATE REVASCULARIZATION IN HEART FAILURE: BIOPOLYMERIC DELIVERY OF A SYNERGISTIC COMBINATION OF ANGIOGENIC GROWTH FACTORS
The aim of this study was to investigate the effects of novel growth factor combinations and to evaluate their angiogenic effects in vivo following delivery with a new biodegradable polymer system. First, we found that FGF-2 (Fibroblast Growth Factor-2) and HGF (Hepatocyte Growth Factor) display synergistic stimulatory effects on the migration and proliferation of murine endothelial cells in vitro. Furthermore, we show that whereas HGF potentiates the proliferative effect of FGF-2 in smooth muscle cells, the HGFinduced mobility response in these cells is enhanced by FGF-2. The molecular mechanisms of the reciprocal stimulatory effects involve upregulation in endothelial cells of the HGF receptor, c-Met, by FGF-2, and vice versa upregulation of the FGFR-1 by HGF stimulation.
Next, we determined the release potential of a new polymeric delivery system based on biodegradable alginate microparticules adapted for cardiac injection. We found that FGF-2 is liberated during less than 1 month with a strong initial level of release during the À rst ten days. In contrast, HGF is continuously liberated during 40 days with a maximal release around day eighth. Our in vivo data, from a Matrigel plug assay in mice, indicate a signiÀ cantly increased efÀ cacy of angiogenic therapy using growth factors delivered by alginate polymers. Moreover, we found that a combination of HGF and FGF-2 displays a potent synergistic angiogenic effect in vivo.
In conclusion, we demonstrate the potential of the speciÀ c combination of FGF-2 and HGF in obtaining a synergistic stimulatory effect in vitro and in vivo. Further, our new alginate-based injectable polymeric system seems well adapted for delivery of growth factors for therapeutic angiogenic approaches to ameliorate cardiac perfusion D013 Bone marrow-derived endothelial progenitor cells (EPCs), present in the systemic circulation, are augmented in response to tissue ischemia, and incorporate into sites of neovascularization. They possess the ability to differentiate into endothelial cells (ECs). Microparticles (MPs), small fragments generated from the plasma membrane, are able to activate the angiogenic program of ECs through mRNA transfer. Also, Peroxisome Proliferator-Activated Receptor (PPAR) alpha agonists increase cardiac progenitor differentiation. Here, we have studied the effects of circulating MPs obtained from PPARalpha wild type (WT) and knock-out (KO) mice on EPC differentiation and in vitro capillary-like tube formation of ECs.
PPAR-ALPHA IS ESSENTIAL FOR MICROPARTICLE-INDUCED DIFFERENTIATION OF BONE MARROW-DERIVED ENDOTHELIAL PROGENITOR CELLS AND IN VITRO ANGIOGENESIS
MPs were obtained from blood of mice, and MP sub-populations were characterized by Á ow cytometer. EPCs were isolated from WT mice using density gradient separation. Isolated cells were cultured in the absence or presence of MPs from PPARalpha WT or KO mice for 7 days. Then, expression of speciÀ c markers of EPCs (Sca-1/ Flk-1) were analysed by Á ow cytometry or dual binding of FITClabeled BS I lectin and Dil-acetylated-LDL by confocal microscopy. Also, ECs were isolated from WT mice aorta. The effects of 24 hours incubation with MPs from PPARalpha WT or KO mice on in vitro angiogenesis were assessed by capillary-like tube formation assay on Matrigel.
Circulating MPs from PPARalpha mice were mainly derived from platelets and leucocytes. MP levels were not signiÀ cantly different between strains. Only MPs from PPARalpha WT mice harbored PPARalpha. Incubation of EPCs with MPs from PPARalpha WT, but not from KO mice, increased signiÀ cantly the number of differentiated EPCs. Incubation of ECs with PPARalpha WT-derived MPs increased capillary-like tube formation of ECs. By contrast, deletion of PPARalpha markedly inhibited in vitro tube formation of ECs.
Our results suggest that the presence of PPARalpha in MPs, not only stimulates EPCs differentiation, but also favored in vitro
